Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 116, Issue 1-2, 2009, Pages 29-36

  Dovio, Andrea ^a   Sartori, Maria Luisa ^a   De Francia, Silvia ^a   Mussino, Stefano ^a   Perotti, Paola ^a   Saba, Laura ^a   Abbadessa, Giuliana ^a   Racca, Silvia ^a   Angeli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

11 Hydroxysteroid dehydrogenase; Glucocorticoid receptor; Interleukin 6; Mineralocorticoid receptor; Osteoprotegerin; Prostate cancer

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; ANDROGEN; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; OSTEOPROTEGERIN; RADIOLIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; WESTERN BLOTTING;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANDROGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1BETA; MALE; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID;

EID: 67449103077     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.04.007     Document Type: Article

References (27)

1. Fakih M., Johnson C.S., and Trump D.L. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60 4 (2002) 553-561
2. Chen S., Wang J., Yu G., Liu W., and Pearce D. Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J. Biol. Chem. 272 22 (1997) 14087-14092
3. Nishimura K., Nonomura N., Satoh E., et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 93 22 (2001) 1739-1746
4. Li Z., Chen Y., Cao D., Wang Y., Chen G., Zhang S., and Lu J. Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 147 11 (2006) 5259-5267
5. Tenta R., Sourla A., Lembessis P., Luu-The V., and Koutsilieris M. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm. Metab. Res. 37 10 (2005) 593-601
6. Yano A., Fujii Y., Iwai A., Kageyama Y., and Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin. Cancer Res. 12 10 (2006) 3003-3009
7. Yano A., Fujii Y., Iwai A., Kawakami S., Kageyama Y., and Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin. Cancer Res. 12 20 pt1 (2006) 6012-6017
8. Lou Y.R., Murtola T., and Tuohimaa P. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 94 1-3 (2005) 151-157
9. Duma D., Jewell C.M., and Cidlowski J.A. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102 1-5 (2006) 11-21
10. Dovio A., Masera R.G., Sartori M.L., Racca S., and Angeli A. Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif. Tissue Int. 69 5 (2001) 293-298
11. Gill P.S., Regmi A., Porter-Gill P.A., and Kasckow J.W. Interleukin-1 regulation of corticotropin-releasing factor (CRF), glucocorticoid receptor, c-fos and c-jun messenger RNA in the NPLC-KC cell line. Mol. Cell. Endocrinol. 137 1 (1998) 31-39
12. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., and Stewart P.M. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25 5 (2004) 831-866
13. Rossier M.F., Lesouhaitier O., Perrier E., Bockhorn L., Chiappe A., and Lalevée N. Aldosterone regulation of T-type calcium channels. J. Steroid Biochem. Mol. Biol. 85 2-5 (2003) 383-388
14. Pagé N., Warriar N., and Govindan M.V. 11beta-Hydroxysteroid dehydrogenase and tissue specificity of androgen action in human prostate cancer cell LNCaP. J. Steroid Biochem. Mol. Biol. 49 2-3 (1994) 173-181
15. Nath N., Lakshmi V., and Rosenthal J.C. Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP. Prostate 23 3 (1993) 225-233
16. Garthwaite S.M., and McMahon E.G. The evolution of aldosterone antagonists. Mol. Cell. Endocrinol. 217 1-2 (2004) 27-31
17. Pascual-Le Tallec L., and Lombès M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol. Endocrinol. 19 9 (2005) 2211-2221
18. Pascual-Le Tallec L., Demange C., and Lombès M. Human mineralocorticoid receptor A and B protein forms produced by alternative translation sites display different transcriptional activities. Eur. J. Endocrinol. 150 4 (2004) 585-590
19. Kim H.J., Park Y.I., and Dong M.S. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays. Toxicol. In Vitro 20 7 (2006) 1159-1167
20. Cleutjens C.B., Steketee K., van Eekelen C.C., van der Korput J.A., Brinkmann A.O., and Trapman J. Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 138 12 (1997) 5293-5300
21. Scholz I.V., Cengic N., Göke B., Morris J.C., and Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J. Clin. Endocrinol. Metab. 89 3 (2004) 1108-1116
22. Yemelyanov A., Czwornog J., Chebotaev D., Karseladze A., Kulevitch E., Yang X., and Budunova I. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26 13 (2007) 1885-1896
23. Mohler J.L., Chen Y., Hamil K., Hall S.H., Cidlowski J.A., Wilson E.M., French F.S., and Sar M. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin. Cancer Res. 2 5 (1996) 889-895
24. Balakumaran B.S., and Febbo P.G. New insights into prostate cancer biology. Hematol. Oncol. Clin. N. Am. 20 4 (2006) 773-796
25. Domingo-Domenech J., Oliva C., Rovira A., Codony-Servat J., Bosch M., Filella X., Montagut C., Tapia M., Campás C., Dang L., Rolfe M., Ross J.S., Gascon P., Albanell J., and Mellado B. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12 18 (2006) 5578-5586
26. George D.J., Halabi S., Shepard T.F., Nicholas J., Vogelzang J., Hayes D.F., Small J.E., and Kantoff P.W. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B9480. Clin. Cancer Res. 11 5 (2005) 1815-1820
27. Holen I., Croucher P.I., Hamdy F.C., and Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62 13 (2002) 1619-1623